 | This biographical article is written like a résumé. (December 2020) |
Thomas Oxley | |
|---|---|
 Dr. Thomas Oxley | |
| Born | |
| Education | Monash University, MD University of Melbourne, PhD Neural Engineering |
| Years active | 2012-Present |
| Known for | Interventional Neurologist CEO, Synchron, Inc. |
| Medical career | |
| Profession | Neurointerventionalist, CEO |
| Field | Neurology |
| Institutions | Synchron, Inc., University of Melbourne |
| Website | synchron.com |
Thomas J. Oxley is the chief executive officer of Synchron and neurointerventionist at Mount Sinai Hospital in New York City.[1] Trained as a vascular and interventional neurologist, he established the Vascular Bionics laboratory at the University of Melbourne and is currently co-head of this lab.[2] Oxley is best known for founding Synchron, a company building next-generation brain computer interface solutions that has recently announced the first clinical data on a novel stent electrode (Stentrode) neural interface that is inserted through blood vessels. The company was initiated sometime after his cold-call to DARPA for funding, and has received substantial funding from the U.S. Defense Advanced Research Projects Agency (DARPA) and the Australian government to research this minimally-invasive neural interface technology.[3]
- ^ "Thomas Oxley at Mt. Sinai". www.mountsinai.org. Retrieved 27 June 2019.
- ^ "University of Melbourne Vascular Bionics Laboratory". medicine.unimelb.edu.au. 2 April 2019. Retrieved 27 June 2019.
- ^ "Thomas Oxley, University of Melbourne". findanexpert.unimelb.edu.au. Retrieved 27 June 2019.